所有图片(1)
别名:
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
经验公式（希尔记法）:
C25H34O6
CAS号:
分子量:
430.53
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
certified reference material
pharmaceutical secondary standard
质量水平
Agency
traceable to BP 793
traceable to Ph. Eur. B1157300
traceable to USP 1078201
API类
budesonide
CofA
current certificate can be downloaded
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
InChI
1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
InChI key
VOVIALXJUBGFJZ-KWVAZRHASA-N
基因信息
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般描述
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Budesonide is a nonsystemic glucocorticoid and an epimeric mixture, where both the epimers have similar anti-inflammatory activity. It is widely used in the treatment of Crohn′s disease.
Budesonide is a nonsystemic glucocorticoid and an epimeric mixture, where both the epimers have similar anti-inflammatory activity. It is widely used in the treatment of Crohn′s disease.
应用
Budesonide may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using high-performance liquid chromatography technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
生化/生理作用
Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.
分析说明
These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.
其他说明
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
附注
To see an example of a Certificate of Analysis for this material enter LRAB3750 in the slot below. This is an example certificate only and may not be the lot that you receive.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
靶器官
Adrenal gland
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Development and validation of a high-performance liquid chromatographic method for the analysis of budesonide
Gupta M and Bhargava.NH
Journal of Pharmaceutical and Biomedical Analysis, 40(2), 423-428 (2006)
Koremu K Meja et al.
American journal of respiratory cell and molecular biology, 39(3), 312-323 (2008-04-19)
Oxidative stress as a result of cigarette smoking is an important etiologic factor in the pathogenesis of chronic obstructive pulmonary disease (COPD), a chronic steroid-insensitive inflammatory disease of the airways. Histone deacetylase-2 (HDAC2), a critical component of the corticosteroid anti-inflammatory
Topical Steroids in Gastroenterology and Hepatology (2004)
Cumali Efe et al.
Autoimmunity reviews, 11(5), 330-334 (2011-10-18)
The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome. A total of 18 AIH or overlap syndrome patients were
Marek Woynarowski et al.
The Journal of pediatrics, 163(5), 1347-1353 (2013-07-03)
To compare the effect of budesonide vs prednisone therapy both in combination with azathioprine in pediatric patients with autoimmune hepatitis (AIH). Forty-six patients with AIH (11 males and 35 females) aged 9-17 years were enrolled in a 6-month, prospective, double-blind
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门